Impaired apoptosis can allow abnormal survival of cells undergoing neoplastic transformation, thereby facilitating the accumulation of further oncogenic mutations.^[@bib1]^ In addition to promoting the development of neoplastic disease, defects in the apoptotic machinery can also impair the response of tumour cells to various anti-cancer agents.^[@bib1]^

The BCL-2 regulated apoptotic pathway, triggered by various damage signals, is controlled by interactions between the pro- and anti-apoptotic members of the Bcl-2 protein family. The pro-survival members, BCL-2, BCL-X~L~, BCL-W, MCL-1 and A1, are essential for cell survival. The multi-BH domain pro-apoptotic subfamily members BAX and BAK are the critical effectors of apoptosis, responsible for mitochondrial outer membrane permeabilisation and consequent cellular demolition. The pro-apoptotic BH3-only subfamily members, including BIK/NBK/BLK, BAD, BID, HRK/DP5, BIM, NOXA, BMF and PUMA, are activated by diverse developmental signals and stress stimuli and act as cell-type- and stimulus-specific cell death initiators. Different BH3-only proteins have distinct specificities for binding pro-survival BCL-2 proteins. BIM, BID and PUMA are 'promiscuous\', binding avidly to BCL-2 and all its pro-survival homologues, whereas other BH3-only proteins, such as NOXA and BIK, bind only to subsets of pro-survival proteins.^[@bib2]^ According to the 'direct activation\' model, certain BH3-only proteins (called 'activators\'), such as BIM, BID and PUMA, can directly bind and activate BAX/BAK.^[@bib3]^ Conversely, the 'indirect model\' posits that cell death is initiated when all pro-survival BCL-2 proteins sequestering BAX/BAK are neutralised by BH3-only proteins, thereby unleashing the pro-apoptotic actions of BAX/BAK.^[@bib4]^

BIK/BLK/NBK was identified in a screen for interactors with BCL-2, BCL-X~L~ or the viral analogue E1B19 kD.^[@bib5],\ [@bib6]^ Although Bik is widely expressed, mice lacking Bik display no overt abnormalities.^[@bib7]^ Non-transformed hematopoietic cells and fibroblasts from BIK-deficient mice respond normally to apoptotic stimuli, such as treatment with DNA-damaging chemotherapeutic drugs (e.g., etoposide) indicating that BIK may have overlapping functions with other BH3-only proteins.

BIK is proposed to function as a tumour suppressor (see review Chinnadurai *et al.*^[@bib8]^). Deletions in regions of chromosome 22q, encompassing the *BIK* gene, have been reported in human colorectal as well as head and neck cancers and gliomas. Loss of heterozygosity at the *BIK* locus has been observed in renal cell carcinomas. Mutations within the *BIK* gene were found in human B-cell lymphomas and microarray analyses have revealed epigenetic silencing of *BIK* in multiple myeloma-derived cell lines.

To assess the tumour suppressor potential of Bik, we have examined the impact of Bik deficiency on lymphomagenesis in E*μ*-*Myc* transgenic mice, which develop pre-B or B-cell lymphoma resulting from c-Myc overexpression followed by acquisition of additional oncogenic mutations.^[@bib9],\ [@bib10]^ We found that loss of Bik, even in combination with loss of Noxa (which has a binding specificity complementary to Bik), did not accelerate E*μ*-*Myc-*induced lymphomagenesis.

BIK-induced apoptosis has mainly been demonstrated in epithelial cancer-derived cell lines using *in vitro* overexpression systems.^[@bib5],\ [@bib6],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16]^ The role of endogenous Bik in chemotherapeutic drug-induced killing of cancer cells has not been examined in detail. Curiously, reports have described both p53-dependent^[@bib17],\ [@bib18]^ and p53--independent^[@bib19],\ [@bib20]^ transcriptional induction of *Bik* in response to anti-cancer therapeutics in human tumour-derived cell lines but the relevance of these findings is unclear. We have previously shown that Bik loss does not alter sensitivity of E*μ*-*Myc* lymphoma cells with functional p53 to apoptosis induced by etoposide *in vitro.*^[@bib21]^ We show here that neither loss of Bik alone, nor the combined deficiency of Bik and Noxa, affect sensitivity of E*μ*-*Myc* lymphomas to the DNA-damaging chemotherapeutic drug, cyclophosphamide (CTX) *in vivo* and demonstrate that loss of Bik and Noxa can be adequately compensated for by other BH3-only proteins in the response of lymphoma cells to DNA-damaging chemotherapy.

Results
=======

*Bik* is expressed in E*μ*-*Myc* lymphoma cells
-----------------------------------------------

c-Myc overexpression upregulates the expression of the BH3-only genes *Noxa, Puma* and *Bim*^[@bib22]^ and loss of these proteins was shown to accelerate lymphomagenesis in E*μ*-*Myc* transgenic mice.^[@bib22],\ [@bib23],\ [@bib24],\ [@bib25]^ Similarly, pre-leukaemic B220^+^ sIgM^−^ pre-B and B220^+^ sIg^+^ B-lymphoid cells from pre-malignant E*μ*-*Myc* mice (4--6 weeks of age) displayed higher levels of *Bik* mRNA induction (∼5-fold and ∼17-fold increase, respectively) compared with their counterparts from control (nontransgenic, wt) littermates ([Figure 1a](#fig1){ref-type="fig"}). *Bik* is expressed in a diverse range of haematopoietic cell types,^[@bib7]^ however, little has been reported about its levels in neoplastic haematopoietic cells. Higher levels of *Bik* mRNA were observed in E*μ*-*Myc* pre-B lymphoma (∼2-fold increase) and E*μ*-*Myc* B-lymphoma cells (∼7-fold increase) isolated from sick (tumour-bearing) E*μ*-*Myc* transgenic mice compared with normal pre-B and B-lymphoid cells from healthy C57BL/6 mice ([Figure 1b](#fig1){ref-type="fig"}).

Neither loss of Bik nor combined loss of Bik and Noxa accelerate E*μ*-*Myc* lymphoma development
------------------------------------------------------------------------------------------------

Bik is not essential for normal mouse development and unstressed *Bik*^−/−^ mice display no haematopoietic abnormalities despite its widespread expression in the haematopoietic compartment.^[@bib7]^ We examined the effect of BIK deficiency on E*μ*-*Myc-*induced lymphomagenesis. E*μ*-*Myc* mice (*n*=68) displayed a median survival of 106 days and E*μ*-*Myc/Bik*^−/−^ (*n*=30) mice succumbed at a similar rate with a median survival of 109 (E*μ*-*Myc/Bik*^−/−^ vs E*μ*-*Myc P*=0.433) ([Figure 2a](#fig2){ref-type="fig"}). Severity of disease manifestation in E*μ*-*Myc/Bik*^−/−^ mice was comparable to that reported in control E*μ*-*Myc* mice^[@bib9],\ [@bib10]^ with conspicuous enlargement of lymph nodes, spleen and thymus.

Given the complementary binding patterns of the BH3-only proteins NOXA (MCL-1, A1) and BIK (BCL-2, BCL-X~L~, BCL-W) to pro-survival BCL-2 family members^[@bib2],\ [@bib26]^ and the report that, when enforcibly expressed, these two BH3-only proteins can cooperate to induce BAX activation, resulting in mitochondrial release of cytochrome *c*,^[@bib15]^ we generated E*μ*-*Myc* mice doubly-deficient for Noxa and Bik. As reported previously,^[@bib22]^ loss of Noxa did not significantly affect E*μ*-*Myc*-induced lymphomagenesis with E*μ*-*Myc/Noxa*^−/−^ mice displaying a median survival of 133 days (*n*=64) compared with a median survival of 106 days in control E*μ*-*Myc* mice (*n*=68) ([Figure 2a](#fig2){ref-type="fig"}). Even the combined loss of both Bik and Noxa did not accelerate E*μ*-*Myc-*induced lymphomagenesis (median survival 100 days; *n*=27; [Figure 2a](#fig2){ref-type="fig"}).

qRT-PCR analysis of E*μ*-*Myc/Bik*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ lymphomas showed no significant differences in expression levels of the pro-apoptotic BH3-only genes *Bad, Bim, Bmf, Puma, Noxa,* or of the pro-survival *Bcl-2* family genes, *Bcl-2, Bcl-x, Mcl-1* when compared with control E*μ*-*Myc* lymphoma cells ([Figure 3a](#fig3){ref-type="fig"}). These results demonstrate that loss of *Bik*, or even combined loss of *Bik* and *Noxa*, two BH3-only proteins with complementary binding specificity for Bcl-2-like pro-survival proteins, does not cause compensatory upregulation of the other remaining BH3-only genes, or changes in expression of pro-survival *Bcl-2* genes at the transcript level.

Loss of Bik alone, or in combination with Noxa loss has no effect on disease severity or lymphoma subtype in E*μ*-Myc transgenic mice
-------------------------------------------------------------------------------------------------------------------------------------

Immunophenotyping of primary lymphomas revealed that the majority were either B220^+^ sIgM^−^ pre-B lymphomas or B220^+^ sIgM^+^ B-cell lymphomas, whereas a small minority displayed a mixed population of both sIgM^−^ and sIgM^+^ lymphoma cells. The overall proportions of pre-B and sIg^+^ B-cell lymphomas were not significantly altered as a result of Bik deficiency (9/25 Pre-B, 14/25 B) or combined Noxa and Bik deficiency (10/16 pre-B and 5/16 B), compared with control E*μ*-*Myc* (9/21 pre-B, 11/21 B), and E*μ*-*Myc/Noxa*^−/−^ (7/23 pre-B, 11/23 B) mice ([Figure 3b](#fig3){ref-type="fig"}).

Differences in tumour onset depending on tumour immunophenotype in E*μ*-*Myc* mice lacking single BH3-only proteins have been documented. Loss of BIM, PUMA, BMF or BAD accelerated E*μ*-*Myc* B-cell lymphoma development while the onset of pre-B lymphomas was not altered.^[@bib22],\ [@bib23],\ [@bib25]^ These data indicate that BH3-only proteins exert differentiation stage-specific suppressive effects on lymphomagenesis and highlight the necessity of analysing the impact of BH3-only protein deficiencies on tumourigenesis, with respect to immunophenotype. Tumour onset in E*μ*-*Myc,* E*μ*-*Myc/Bik*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ mice was therefore stratified according to pre-B or B lymphoma subtype. No significant differences in survival were observed between E*μ*-*Myc/Bik*^−/−^ mice bearing pre-B (median survival 145 days, *n*=9) or mature B cell (median survival 128 days, *n*=11) lymphomas versus control E*μ*-*Myc* mice bearing pre-B (median survival 202 days, *n*=10) or B cell (median survival 125 days, *n*=14) lymphomas ([Figure 2b](#fig2){ref-type="fig"}). Similarly, the survival of E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ mice bearing pre-B or mature B-cell lymphomas (median survival 117 days and 165 days, respectively) did not differ significantly from the survival of control E*μ*-*Myc,* E*μ*-*Myc/Bik*^−/−^ or E*μ*-*Myc/Noxa*^−/−^ (median survival pre-B 134 days, B cell 104 days) lymphoma-bearing mice ([Figure 2b](#fig2){ref-type="fig"}).

Analysis of peripheral blood of sick E*μ*-*Myc/Bik*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ mice at death revealed no significant differences in leukaemic burden or lymphocyte counts compared with sick control E*μ*-*Myc* or E*μ*-*Myc/Noxa*^−/−^ mice ([Figures 3c and d](#fig3){ref-type="fig"}). Spleen weights from E*μ*-*Myc/Bik*^−/−^ mice at autopsy were significantly, albeit modestly (*P*=0.02), greater than those observed for spleens from control E*μ*-*Myc* mice ([Figure 3e](#fig3){ref-type="fig"}). Histological examination of organs from sick E*μ*-*Myc/Bik*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ mice showed similar extent of tumour infiltration into lymph nodes, spleen, thymus, liver, lung and kidney to that seen in control E*μ*-*Myc* mice ([Figure 4](#fig4){ref-type="fig"}, [Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

The incidence of p53 pathway mutations in E*μ*-*Myc* lymphomas is not altered as a result of Bik deficiency or combined deficiency of Noxa and Bik
--------------------------------------------------------------------------------------------------------------------------------------------------

There is significant pressure for the p19^ARF^ -- p53 pathway to be compromised during E*μ*-*Myc-*induced lymphoma development.^[@bib27]^ Loss of certain BH3-only proteins, such as BIM,^[@bib23],\ [@bib28]^ PUMA^[@bib22],\ [@bib24]^ or BMF^[@bib25]^ can alleviate the need for p53 pathway mutations in E*μ*-*Myc* lymphomas. We detected no spontaneous deletions of the *p16*^*Ink4a*^*/p19*^*Arf*^ locus by genomic PCR in a panel of randomly selected E*μ*-*Myc/Bik*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ lymphomas ([Figure 5a](#fig5){ref-type="fig"}).

As p53 normally regulates p19^ARF^ protein expression by a negative feedback loop in healthy cells^[@bib27]^ ([Figure 5d](#fig5){ref-type="fig"}), the levels of p19^ARF^ as well as p53 protein were examined by western blotting in a panel of randomly selected E*μ*-*Myc/Bik*^−/−^, E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ and control E*μ*-*Myc* lymphomas. In these assays high levels of p19^ARF^ indicate loss of p53 function because of impaired negative regulation;^[@bib29]^ and high levels of p53 indicate mutant, stabilised p53. High p19^ARF^ and/or p53 protein levels were detected in 3/20 (15%) E*μ*-*Myc/Bik*^−/−^ and in 3/10 (30%) E*μ*-*Myc/Noxa*^−/−^ ([Figures 5b and c](#fig5){ref-type="fig"}) lymphomas. This prevalence was comparable to that seen in control E*μ*-*Myc* lymphomas (2/15 (13.3%) as well as to the previously published incidence of 3/10 (30%) in E*μ*-*Myc/Noxa*^−/−^ lymphomas.^[@bib22]^

p53-independent *Bik* induction occurs following DNA-damaging drug treatment in E*μ*-*Myc* lymphomas
----------------------------------------------------------------------------------------------------

Stable cell lines were generated from lymphomas from sick control E*μ*-*Myc* or p53-deficient E*μ*-*Myc* mice. Upon *in vitro* treatment of control E*μ*-*Myc* and E*μ*-*Myc/p53*^−/−^ lymphoma cell lines with 0.2 *μ*g/ml etoposide for 3, 6 or 8 h, only negligible induction of *Bad, Bid* and *Bmf* was observed ([Figure 6a](#fig6){ref-type="fig"}). *Bim* mRNA, concordant with our previous findings,^[@bib21]^ was markedly induced in E*μ*-*Myc* lymphoma cell lines and was significantly less pronounced in E*μ*-*Myc* lymphoma cell lines lacking p53. Similarly, *Bik* mRNA was upregulated, albeit at slightly lower magnitude than *Bim* (∼4-fold vs ∼8-fold at 6 h, respectively; [Figure 6a](#fig6){ref-type="fig"}). However, in contrast to *Bim, Bik* mRNA induction (∼3-fold at 6 h and ∼7-fold at 8 h) was also upregulated at similar levels in E*μ*-*Myc/p53*^−/−^ lymphoma cell lines ([Figure 6a](#fig6){ref-type="fig"}), demonstrating that this transcriptional induction is p53-independent.

Loss of Bik alone, or in combination with Noxa loss does not render E*μ*-*Myc* lymphoma cells resistant to DNA-damaging drug-induced killing
--------------------------------------------------------------------------------------------------------------------------------------------

Although *Bik* mRNA is induced in E*μ*-*Myc* lymphoma cells following etoposide treatment, we have shown previously that E*μ*-*Myc/Bik*^−/−^ lymphoma cell lines display sensitivity to etoposide, comparable to that of conventional E*μ*-*Myc* lymphoma cell lines.^[@bib21]^ The potential for important co-operation between BIK and other BH3-only proteins could not be excluded. We therefore investigated the possible co-operation between BIK and NOXA in DNA damage-induced killing of lymphoma cells. Analysis of stable cell lines from four independent lymphomas arising in E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ mice revealed that concomitant loss of BIK and NOXA did not afford significant protection from etoposide-induced killing ([Figure 6b](#fig6){ref-type="fig"}).

The role of Bik in DNA-damaging drug-induced apoptosis was further assessed *in vivo* by transplanting primary lymphomas into immuno-competent C57BL/6-recipient mice. Once tumours became palpable, the mice were treated with CTX at either 200 or 300 mg/kg body weight (the maximum tolerated dose^[@bib21]^). Kaplan--Meier survival curves for mice bearing control E*μ*-*Myc* (*n*=17), E*μ*-*Myc/Bik*^−/−^ (*n*=7), E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ (*n*=6) and E*μ*-*Myc* (p53 mutant) (*n*=4) lymphomas treated with CTX are shown in [Figure 6c](#fig6){ref-type="fig"}. For mice bearing control E*μ*-*Myc* lymphomas that were treated with either 200 or 300 mg/kg body weight of CTX, a median survival of 102 or 176 days post treatment was observed, respectively, compared with only 5 days for control E*μ*-*Myc* lymphoma-bearing mice treated with vehicle alone ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). A similar prolongation in survival was observed following CTX treatment of mice bearing E*μ*-*Myc/Bik*^−/−^ (80 and 86 days for 200 or 300 mg/kg body weight of CTX, respectively) or E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ (58 and 175 days for 200 or 300 mg/kg body weight of CTX, respectively) lymphomas, compared with only 2 to 8 days for mice treated with vehicle alone ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}).

The *in vivo* survival data were analysed using Cox proportional hazards models, taking into account the correlation between recipient mice. No significant difference post-CTX treatment was observed between the survival of mice bearing control E*μ*-*Myc* (blue curves) and E*μ*-*Myc/Bik*^−/−^ (orange curves) lymphomas (*P*=0.869 for 200 mg/kg body weight CTX, *P*=0.336 for 300 mg/kg body weight CTX) or between the survival of mice bearing control E*μ*-*Myc* (blue curves) and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ (green curves) lymphomas (*P*=0.637 for 200 mg/kg body weight CTX; *P*=0.212 for 300 mg/kg body weight CTX) ([Figure 6c](#fig6){ref-type="fig"}). As expected, E*μ*-*Myc* lymphomas with a mutated p53--p19^ARF^ pathway (red curves) displayed profound resistance to CTX and mice bearing such tumours died rapidly following treatment. Consistent with the *in vitro* data, neither lymphomas lacking Bik alone, nor those lacking both Bik and Noxa, displayed an increase in resistance to CTX treatment *in vivo* compared with lymphomas with endogenous levels of Bik and Noxa.

Discussion
==========

Bik-deficient mice develop normally with a normal lifespan.^[@bib7]^ Non-transformed haematopoietic cells and fibroblasts from these mice respond normally to various apoptotic stimuli, including DNA damage.^[@bib7]^ Although these results would suggest functional redundancy between BIK and other pro-apoptotic BH3-only proteins, BIK has been proposed to function as a tumour suppressor in several human cancers, including some lymphoid malignancies.^[@bib8]^

Apoptosis triggered by c-Myc overexpression is regulated by the BCL-2 protein family ^[@bib30],\ [@bib31]^ and is thought to impose a major barrier to MYC-induced lymphoma development. Accordingly, overexpression of pro-survival BCL-2^[@bib32]^ or loss of BH3-only proteins that have potent killing capacity, such as BIM^[@bib23],\ [@bib28]^ and PUMA^[@bib22],\ [@bib24]^ can significantly accelerate MYC-induced lymphomagenesis in mice. A recent study showed that loss of the more 'selective\' binders, and therefore less potent BH3-only proteins, BMF and BAD, can also accelerate E*μ*-*Myc-*driven lymphomagenesis.^[@bib25]^ These data are somewhat surprising given that theoretically, the promiscuous BIM or PUMA could adequately compensate for loss of either BMF or BAD. These findings indicate that the role of selective BH3-only proteins in tumour suppression may not simply be redundant to the functions of 'potent\' BH3-only proteins and the control of survival of cells undergoing neoplastic transformation is not solely dictated by the sequestration of pro-survival BCL-2 family proteins.^[@bib33]^ We therefore reasoned that BIK might also constrain tumour development in the context of c-MYC overexpression.

*Bik* mRNA expression levels were modestly elevated in pre-leukaemic, B-lymphoid cells from pre-malignant E*μ*-*Myc* mice compared with those from control (WT) mice. Moreover, lymphoma cells from sick E*μ*-*Myc* mice also expressed readily detectable levels of *Bik* mRNA. These observations support the notion that BIK may have a role in suppression of E*μ*-*Myc*-induced lymphomagenesis. Induction of apoptosis by c-MYC overexpression is attributable in part to activation of the p19^ARF^-- p53 pathway, in which p19^ARF^ upregulation prevents the degradation of p53 by sequestration of the ubiquitin ligase MDM2.^[@bib27],\ [@bib34]^ The link between *Bik* levels and *p53*, however, is controversial. Although putative p53 binding sites have been identified in the promoter of the *Bik* gene^[@bib35]^ and ectopic overexpression of p53 has been shown to robustly induce *Bik* expression,^[@bib17]^ a p53 response could not be detected in promoter/reporter assays.^[@bib17],\ [@bib18]^ c-MYC overexpression can, however, also induce apoptosis independent of p53^[@bib18],\ [@bib27]^ and thus, the elevation of *Bik* we observed may be critical for apoptosis induction independent of p53.

Despite evidence of loss of BIK expression in human tumours,^[@bib8]^ in the E*μ*-*Myc* transgenic mouse model, loss of BIK was insufficient to accelerate lymphoma onset or increase disease severity. Time to tumour morbidity (when animals have to be killed) has been demonstrated to differ according to immunophenotype (sIgM^−^ pre-B or sIgM^+^ B cell) of lymphomas in E*μ*-*Myc* mice lacking certain BH3-only genes. For example, loss of BIM, PUMA, BMF or BAD accelerated development of E*μ*-*Myc* B-cell lymphoma while the onset of pre-B lymphoma was unaltered.^[@bib22],\ [@bib23],\ [@bib25]^ Moreover, loss of NOXA delayed the onset of E*μ*-*Myc* pre-B lymphomas but not E*μ*-*Myc* B-cell lymphomas.^[@bib22]^ In comparison, BIK deficiency had no impact on pre-B or B-cell E*μ*-*Myc* lymphoma development, implying that BIK may have overlapping functions with other BH3-only proteins. BIK may still be a barrier to tumour development in other cell types, both haematological and nonhaematological, or in tumourigenesis driven by distinct oncogenic lesions (unrelated to c-MYC overexpression). Alternatively, the lack of effect on tumourigenesis may reflect BIK\'s ability to sequester only select pro-survival BCL-2 family proteins.^[@bib2],\ [@bib26]^ Therefore, the disturbance of the overall balance between pro-apoptotic and anti-apoptotic BCL-2 family members caused by BIK loss would be relatively minor, as loss of BIK can theoretically be compensated for by several other (selective binding) pro-apoptotic BH3-only proteins (such as BMF and BAD) and loss of BIK would not be expected to impact on inhibition of either MCL-1 or A1.

The lack of protection of E*μ*-*Myc* lymphomas from DNA-damaging drug-induced killing conferred by loss of BIK stands in contrast to studies in which ectopic overexpression of BIK was used to potently induce apoptosis in tumour-derived cell lines.^[@bib5],\ [@bib6],\ [@bib11],\ [@bib12],\ [@bib14]^ Overexpression may allow BIK to artificially interact with and inhibit a wider array of pro-survival BCL-2 proteins^[@bib2],\ [@bib5],\ [@bib6]^ than does endogenous BIK, expressed under physiological conditions. Nonetheless, it is curious that we and others^[@bib19],\ [@bib20]^ have observed a modest induction of *Bik* following DNA damage, independent of p53. As its loss had little impact on the apoptotic response of lymphoma cells, it is unclear whether *Bik* induction contributes to apoptosis induction in this setting. The p53-independent upregulation of *Bik* may function to amplify the response to DNA-damaging drugs observed in E*μ*-*Myc* lymphomas that is elicited by the major p53-dependent apoptosis inducers, PUMA and NOXA.

Enforced co-expression of BIK and NOXA can cooperate potently in killing mouse embryonic fibroblasts (MEFs)^[@bib2]^ and in H1299 cells, to synergise in inducing BAX activation and cytochrome *c* release from mitochondria.^[@bib15]^ This cooperative action is presumably due to the complementary nature of their binding abilities to pro-survival BCL-2 family members.^[@bib2]^ BIK and NOXA together can theoretically complement one another to allow sufficient neutralisation of all pro-survival BCL-2-like proteins in a cell to promote more potent apoptosis induction than would be possible with sole expression of either protein. We have found, however, that a combined deficiency in BIK and NOXA is not sufficient for acceleration of E*μ*-*Myc*-induced lymphoma development or to increase resistance of E*μ*-*Myc* lymphoma cells to DNA-damaging drug-induced apoptosis indicating that other BH3-only proteins, such as potent family members, PUMA and BIM, can still adequately compensate for their loss. Loss of both BIK and NOXA did not significantly alter the transcription of other pro-apoptotic BH3-only genes, such as *Bad, Bim, Puma* and *Bmf* or pro-survival genes, such as *Bcl-2, Bcl-xl* or *Mcl-1*, although alterations in the post-transcriptional regulation of these BCL-2 family members cannot be excluded.

Functionally relevant inhibition of the apoptotic signalling pathway downstream of p53, such as that afforded by loss of PUMA or by the combined loss of PUMA and NOXA, have been shown to diminish the pressure for p19^ARF^-- p53 pathway mutations in c-MYC overexpression-driven lymphomas,^[@bib22],\ [@bib24]^ as has loss of BIM^[@bib23]^ or BMF (but not loss of BAD).^[@bib25]^ Deficiency in BIK alone was not able to diminish the selection for loss of p53 function, indicating that loss of BIK cannot compensate for loss of p53. This indicates that the levels of the more potent (promiscuous binding) BH3-only proteins PUMA and BIM are sufficient in E*μ*-*Myc* transgenic pre-B/B-lymphoid cells to delay neoplastic progression.

Collectively, studies of BH3-only gene deletion in the E*μ*-*Myc* lymphoma model highlight the intricacies of apoptotic regulation in response to oncogene activation and DNA damage. The life or death fate of cells undergoing neoplastic progression or of transformed cancer cells following treatment with anti-cancer drugs must not simply be governed by the overall balance of pro- and anti-apoptotic BCL-2 family members, but instead requires the activation of distinct BH3-only proteins for apoptosis induction in a cell-type- and stimulus-specific manner. Thus Bik, even in combination with Noxa, is not a potent suppressor of c-Myc-driven tumourigenesis or critical for chemotherapeutic drug-induced killing of Myc-driven tumours.

Materials and Methods
=====================

Materials
---------

Etoposide and CTX were purchased from Sigma (Castle Hill, NSW, Australia), QVD-OPH (MP Biomedicals, Aurora, OH, USA) was used in experiments at a final concentration of 25 *μ*M.

Experimental animals
--------------------

All experiments with mice were performed according to the guidelines of The Walter and Eliza Hall Institute of Medical Research Animal Ethics Committee. The E*μ*-*Myc* transgenic mice expressing the c-*Myc* oncogene under the control of the immunoglobulin heavy chain gene enhancer (E*μ*)^[@bib9],\ [@bib10]^ have been backcrossed with C57BL/6 mice for \>20 generations. The origins of the *Noxa*^−/−^,^[@bib36]^ *Bik*^−/−[@bib7]^ and *p53*^−/−^ ^[@bib37]^ mice (all on a C57BL/6 background) have been described. The former two strains were generated on an inbred C57BL/6 background using C57BL/6-derived ES cells; the *p53*^−/−^ mice were generated on a mixed C57BL/6 × 129SV background, using 129SV-derived ES cells, but were backcrossed with C57BL/6 mice for \>10 generations. E*μ*-*Myc* transgenic males were crossed with *p53*^−/−^ or *p53*^+/−^ females to generate E*μ*-*myc*/*p53*^+/−^ offspring and with *Noxa*^−/−^ or *Bik*^−/−^ females to produce E*μ*-*Myc*/*Noxa*^+/−^ or E*μ*-*Myc*/*Bik*^+/−^ males, which were then crossed with *Noxa*^−/−^ or *Bik*^−/−^ females to yield E*μ*-*Myc*/*Noxa*^−/−^ or E*μ*-*Myc*/*Bik*^−/−^ progeny, respectively, in separate breedings. E*μ*-*Myc*/*Noxa*^−/−^ males were crossed with *Bik*^−/−^*Noxa*^−/−^ double knockout females to generate E*μ*-*Myc*/*Bik*^+/−^*Noxa*^−/−^ males, which were then bred to *Bik*^−/−^*Noxa*^−/−^ females to yield E*μ*-*Myc*/*Bik*^−/−^*Noxa*^−/−^ mice.

E*μ*-*Myc* lymphomas and lymphoma cell lines
--------------------------------------------

E*μ*-*Myc* lymphomas were defined by flow cytometry as either pre-B (B220^+^ sIg^−^) or B-cell lymphomas (B220^+^ sIgM^+^). Lymphoma cells were used for either transplantation into C57BL/6-recipient mice for *in vivo* drug sensitivity analysis or for *in vitro* culture to obtain stable lymphoma cell lines. Lymphoma cell lines were generated by preparing single-cell suspensions from spleen, which were cultured at 37 °C in a humidified 10% CO~2~ incubator in high-glucose Dulbecco\'s modified Eagle\'s medium supplemented with 10% foetal calf serum (JRH Biosciences, Brooklyn, VIC, Australia), 50 *μ*M 2-mercaptoethanol (Sigma) and 100 *μ*M asparagine (Sigma) referred to as FMA.

Western blotting
----------------

Protein samples were size-fractionated by SDS-PAGE and then blotted onto nitrocellulose (Invitrogen, Grand Island, NY, USA) membranes. Membranes were blocked with 5% non-fat dry milk (Devondale, Melbourne, VIC, Australia) in PBS with 0.1% Tween 20 (Sigma) and then probed with antibodies against p53 (CM5, Novacastra, North Ryde, NSW, Australia), p19^ARF^ (AbCam, Waterloo, NSW, Australia) and *β*-ACTIN (clone AC-74, Sigma; used as a loading control). Detection was performed with HRP-conjugated secondary antibodies and enhanced chemiluminescence (Amersham Biosciences, Castle Hill, NSW, Australia).

Quantitative reverse transcription (qRT)-PCR
--------------------------------------------

Cells were given a DNA damage insult (etoposide) in the presence of QVD-OPH to prevent terminal cellular destruction, and RNA was isolated at specific time points following treatment. Total RNA was extracted from 0.5--1 × 10^6^ cells using the TRIzol Reagent (Invitrogen) according to the manufacturer\'s instructions. 0.5--1 *μ*g of total RNA was converted to cDNA using the High Capacity RNA to cDNA kit (Applied Biosystems, Mulgrave, VIC, Australia). For quantitative analysis, the resulting cDNA was subjected to PCR in 10 *μ*l reaction volumes using Taqman Universal PCR Master Mix (Applied Biosystems) with Taqman Gene Expression Assays (Applied Biosystems) and assessed on an ABI-PRISM 7900 thermal cycler (Applied Biosystems). *β*-*Actin* served as an endogenous normalisation control. Data analyses were performed by the comparative threshold cycle method.

Cell death assays
-----------------

E*μ*-*Myc* lymphoma cells were cultured in FMA at a concentration of 25 000--50 000 cells per well in 96-well flat bottom microtiter plates (Falcon, North Ryde, NSW, Australia). Cells were exposed to etoposide/VP16 (Pfizer, West Ryde, NSW, Australia) (1, 0.2 or 0.04 *μ*g/ml) for 6 or 24 h. Cell death was assessed by flow cytometric analysis after staining with propidium iodide (PI; 2 *μ*g/ml) and annexin V-FITC (0.3 *μ*g/ml). The extent of apoptosis induced specifically by treatment with a DNA damage inducing chemotherapeutic drug (percent specific apoptosis) was calculated using the following equation: \[% induced apoptosis -- (% spontaneous apoptosis/100 -- % spontaneous apoptosis)\]. Each independent E*μ*-*Myc* lymphoma-derived cell line was analysed in at least three independent experiments.

*In vivo* lymphoma cell survival analysis post treatment with DNA-damaging drugs
--------------------------------------------------------------------------------

Six- to 8-week-old C57BL/6 female mice were injected (i.v.) on day 0 with 2 × 10^6^ E*μ*-*Myc* lymphoma cells. Mice were treated with CTX (200--300 mg/kg) or vehicle alone when their spleens became palpable (usually 10--16 days post tumour injection). Mice were culled when deemed unwell (lethargy, tremor, hind-leg paralysis, \>5% weight loss, palpable tumour) in accordance with ethical guidelines, or in the absence of symptoms of lymphoma at 180 days post treatment (when these experiments were terminated).

Analysis of *cdkn2a* locus
--------------------------

Multiplex PCR analysis of genomic DNA extracted from lymphoma cells for the *cdkn2a* (p16^Ink4a^/p19^Arf^) locus was performed to reveal gross deletions, using exon-specific primers for *α*-actin, exons 2, 1*α* and 1*β* as previously described.^[@bib38],\ [@bib39]^

Histology
---------

Soft tissues (spleen, lymph nodes, liver, kidney, heart, lung, thymus) and sternum were fixed in 10% buffered formalin. Tissues were embedded in paraffin, sectioned and stained using haematoxylin and eosin.

Statistical analysis
--------------------

Prism (GraphPad Prism, GraphPad Software Inc., La Jolla, CA, USA), Stata 9.2 (StataCorp., College Station, TX, USA) and R ([www.r-project.org](http://www.r-project.org)) software were used for statistical analysis. Two-group comparisons of leukaemic burden, lymphocyte counts and spleen weights used two-tailed *t*-tests assuming equal variances.

Survival data were plotted using Kaplan--Meier curves. Differences in survival time to tumour-related deaths of E*μ*-*Myc* mice of various genotypes were tested using log-rank tests (each independent lymphoma analysed separately). *P* values \< 0.05 were considered to indicate statistical significance.

The survival data on lymphoma-burdened mice following *in vivo* treatment with CTX involved two-levels of biological replication, with many independently derived lymphomas of different genotypes and varying numbers of recipient mice per treatment arm per independent lymphoma (Supplementary Table 2), meaning that the survival times of recipient mice burdened with the same lymphoma were statistically dependent. To produce the Kaplan--Meier plots in [Figure 6c](#fig6){ref-type="fig"}, the median survival time was calculated separately for censored and non-censored mice for each independent lymphoma. The resulting Kaplan--Meier curves correspond to independent lymphoma rather than to recipient mice, and hence are statistically independent. To test whether the survival times of the different genotypes were significantly different, Cox proportional hazards regression models (Cox, 1972) were fitted. The correlations between recipient mice were taken into account using a robust sandwich estimator, implemented as method *stcox cluster* in Stata 9.2, to estimate S.E. from the Cox model.
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A1

:   B-cell lymphoma 2 related protein A1a

BCL-2

:   B-cell lymphoma 2

BCL-W

:   BCL-2-like 2

BCL-X~L~

:   BCL-2 like 1

BH3

:   Bcl-2 homology 3

BAD

:   BCL-2-associated agonist of cell death

BID

:   BH3-interacting domain death agonist

BIK

:   Bcl-2-interacting killer

BIM

:   BCL-2-like 11

BMF

:   BCL-2 modifying factor

CDKN2A

:   cyclin-dependent kindase inhibitor 2A

cDNA

:   complementary DNA

CTX

:   cyclophosphamide

DNA

:   deoxyribose nucleic acid

HRK

:   harakiri

MCL-1

:   myeloid cell leukaemia sequence 1

MEF

:   mouse embryonic fibroblast

MDM2

:   p53 E3 ubiquitin ligase (mouse)

mRNA

:   messenger RNA

NOXA

:   phorbol-12-myristate-13-acetate-induced protein 1

PUMA

:   p53 upregulated modulator of apoptosis

qRT-PCR

:   quantitative reverse-transcriptase polymerase chain reaction

QVD-OPH

:   broad spectrum caspase inhibitor

RNA

:   ribonucleic acid

SDS-PAGE

:   sodium dodecyl sulphate polyacrylamide gel electrophoresis

WT

:   wild-type
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![*Bik* mRNA levels are modestly increased in B-lymphoma cells and pre-malignant lymphoid cells from E*μ*-*Myc* mice compared with control B-lymphoid cells. (**a**) *Bik* mRNA expression is increased in pre-neoplastic B-lymphoid cells and (**b**) in lymphoma cells from sick E*μ*-*Myc* mice. Differences in the levels of mRNA for pro-apoptotic BH3-only genes between FACS-purified pre-B (B220^+^ sIgM^−^) and B (B220^+^ sIgM^+^) cell subsets obtained from healthy 4--6-week-old E*μ*-*Myc* mice (**a**) or from sick lymphoma-bearing E*μ*-*Myc* mice (**b**), compared with the corresponding non-transformed pre-B and B-lymphoid cells from age-matched control C57BL/6 mice. Relative RNA expression levels were calculated by normalising to the *β-actin* signal in each sample, then dividing the values from the E*μ*-*Myc* transgenic B-lymphoid or -lymphoma cells by the value from the control (nontransgenic) cells (represented by the dotted horizontal line at 1). Data represent mean expression±S.E.M. of cells (lymphoma or control non-transformed) from three individual mice of each genotype analysed in three separate experiments. In pre-malignant E*μ*-*Myc* B220^+^ sIgM^+^ B cells, the fold induction of *Bik* mRNA compared with that observed in control nontransgenic B220^+^ sIgM^+^ B cells, was significantly higher (\**P*\<0.05) than the fold induction of *Bad, Bid, Bim* and *Noxa*](cddis201242f1){#fig1}

![Neither loss of Bik, nor combined loss of Bik and Noxa accelerate lymphoma development in E*μ*-*Myc* transgenic mice. (**a**) Kaplan--Meier survival analysis of mice of the indicated genotypes. Differences in tumour onset between E*μ*-*Myc* (*n*=68), E*μ*-*Myc/Noxa*^−/−^ (*n*=64), E*μ*-*Myc/Bik*^−/−^ (*n*=30) and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ (*n*=27) mice were not significant (*P*=0.170, 0.433, 0.321, respectively compared with control E*μ*-*Myc*). (**b**) Loss of BIK alone, or in combination with NOXA loss, in E*μ*-*Myc* mice did not significantly alter the latency or incidence of either pre-B lymphomas (top panel; E*μ*-*Myc n*=10, E*μ*-*Myc/Bik*^−/−^ *n*=9, E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ *n*=10) or B lymphomas (bottom panel; E*μ*-*Myc n*=14, E*μ*-*Myc/Bik*^−/−^ *n*=11, E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ *n*=5) compared with those seen in E*μ*-*Myc* mice](cddis201242f2){#fig2}

![Loss of Bik or combined loss of Bik and Noxa does not alter lymphoma subtype or severity of disease in E*μ*-*Myc* transgenic mice. (**a**) Differences in the levels of mRNA for BCL-2 family members between FACS-purified B220^+^ lymphoma cells harvested from either sick E*μ*-*Myc* mice lacking Bik, lacking both Bik and Noxa, or from sick control E*μ*-*Myc* mice. qRT-PCR analysis was performed on cDNA and relative expression of RNA was calculated by normalising to the *β-actin* signal in each sample, then dividing the value from the E*μ*-*Myc/Bik*^−/−^ or E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ lymphoma cells by the value from the control E*μ*-*Myc* lymphoma cells. Data represent mean expression±S.E.M. of lymphoma cells from three individual mice of each genotype from three separate experiments. (**b**) Proportions of pre-B (sIgM^−^), B cell (sIgM^+^) and mixed pre-B and B-cell lymphomas in sick E*μ*-*Myc*, E*μ*-*Myc/Bik*^−/−^, E*μ*-*Myc/Noxa*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ mice are shown. (**c**) Numbers of white blood cells (WBC) and (**d**) numbers of lymphocytes in the peripheral blood of sick control E*μ*-*Myc,* E*μ*-*Myc/Bik*^−/−^ E*μ*-*Myc/Noxa*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ mice. (**e**) Spleen weights of sick, lymphoma-bearing E*μ*-*Myc*, E*μ*-*Myc/Bik*^−/−^ E*μ*-*Myc/Noxa*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ mice. For (**c**--**e**), each dot represents a single sick (lymphoma-burdened) animal and the mean is represented by a bar. Numbers of E*μ*-*Myc,* E*μ*-*Myc/Bik*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ mice included are 24, 28 and 23, respectively](cddis201242f3){#fig3}

![Combined loss of Bik and Noxa does not increase the severity of disease in E*μ*-*Myc* transgenic mice. Photomicrographs (magnification × 200) of haematoxylin- and eosin-stained paraffin-embedded sections of lymph nodes, spleen, liver and kidneys from representative lymphoma-burdened sick control E*μ*-*Myc*, E*μ*-*Myc/Bik*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ mice (one mouse per genotype shown)](cddis201242f4){#fig4}

![Bik loss, with or without Noxa loss, does not alter the pressure for selection for a mutated p53 pathway during E*μ*-*Myc-*induced lymphoma development. (**a**) Genomic PCR analysis of the Ink4a/Arf locus revealed that none of the E*μ*-*Myc/Bik*^−/−^ or E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ lymphomas examined had a deletion in this gene. Controls include an E*μ*-*Myc* lymphoma cell line known to contain a deletion in the Ink4a/Arf locus (denoted as --ve) and an E*μ*-*Myc* lymphoma known to retain the Ink4a/Arf locus (denoted as +ve). (**b**) Representative western blots of p19^ARF^, p53 and *β*-ACTIN (loading control) in randomly selected control E*μ*-*Myc*, E*μ*-*Myc/Bik*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ lymphomas. Extracts from MEF immortalised with SV40 large T antigen were included as a positive control for p19^ARF^ and p53 overexpression. The E*μ*-*Myc* lymphoma \#280 was included on each blot as a reference lymphoma. (**c**) A graphical representation of the proportions of E*μ*-*Myc,* E*μ*-*Myc/Bik*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ lymphomas analysed with a mutated p19^ARF^--p53 pathway, as determined by western blotting for p53, p19^ARF^ protein. (**d**) Schematic diagram depicting activation of the p19^ARF^--p53 pathway by c-MYC and the negative feedback loop that exists between p53 and p19^ARF^](cddis201242f5){#fig5}

![*Bik* levels are augmented in E*μ*-*Myc* lymphoma cells in response to DNA damage inducing anti-cancer drugs but loss of Bik does not render these lymphoma cells resistant to drug treatment *in vitro* or *in vivo*. (**a**) E*μ*-*Myc* and E*μ*-*Myc/p53*^−/−^ lymphoma cell lines were treated with 0.2 *μ*g/ml of etoposide for 3, 6 or 8 h in the presence of QVD-OPH (25 *μ*M). Lymphoma cells were harvested at the indicated time points post treatment and total RNA extracted. Differences in the levels of mRNA for the BH3-only genes *Bad, Bid, Bik, Bmf* and *Bim* were analysed by qRT-PCR on cDNA. Relative RNA expression levels were calculated by normalising to the *β-actin* signal in each sample, then dividing the values for etoposide treated lymphoma cells by the values for untreated lymphoma cells. Data represent mean expression±S.E.M. of cells from three individual experiments with three independent lymphoma cell lines for each genotype. (**b**) Cell lines derived from independent E*μ*-*Myc* lymphomas of the indicated genotypes were treated with etoposide (0.2 *μ*g/ml) for the indicated times *in vitro* and cell death was assessed by flow cytometry. Data represent mean±S.E.M. from three to seven independent cell lines per genotype, with each cell line analysed in at least three independent experiments. No significant differences were noted, except for the previously reported significant resistance of E*μ*-*myc/p53*^−/−^ cell lines (used here as a control). (**c**) Response of primary E*μ*-*Myc/Bik*^−/−^ and E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ lymphomas to CTX (200 or 300 mg/kg body weight) treatment *in vivo*. Kaplan--Meier survival curves of mice transplanted (day 0) with lymphomas of the indicated genotypes and treated, once lymphomas became palpable at around day 12. Data were pooled from 4--16 independent lymphomas per genotype with 5--10 recipient mice per treatment per independent lymphomas. No significant differences in survival were observed between mice bearing E*μ*-*Myc/Bik*^−/−^, E*μ*-*Myc/Bik*^−/−^*Noxa*^−/−^ or control E*μ*-*Myc* lymphomas](cddis201242f6){#fig6}
